Home › Acute Biphenotypic Leukemia › Oklahoma
Acute Biphenotypic Leukemia clinical trials in Oklahoma
5 studies for Acute Biphenotypic Leukemia are looking for participants at sites in Oklahoma.
Cities in Oklahoma
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Oklahoma Health Sciences Center, Oklahoma City
- Saint Francis Children's Hospital, Tulsa
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Saint Francis Children's Hospital, Tulsa
RecruitingPhase 2
Ages 1 to 18 · All sexes · Updated Aug 10, 2026 · NCT06390319Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
- Saint Francis Children's Hospital, Tulsa
RecruitingPhase 4
Ages 1 to 18 · All sexes · Updated Jul 14, 2026 · NCT06289673From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.